Cell therapy raised over £600k in December 2014. Now new investment from Japan has enabled a company restructuring and an offer to shareholders to either take a share swop or cash - representing an almost 2X gain.
This is Crowdcube's best result to date. Shareholders paid £37 in 2014 and 24 moths later they are being offered £101.
Although it is not all good news.
EIS reliefs which would have been taken by all B shareholders for tax year 2103/14, will have to be recharged if they opt to sell - with interest. They will also be liable to the full extent of any CGT for this tax year, giving them very limited time to adjust if their allowance is already used up.
I suppose you could argue you could get these odds at the bookies. Still it's better than poke in the eye with a blunt stick